Principal Investigator
TBD TBD
- 2 trials
- 1 compound
Therapeutic focus
- Alzheimer's Disease
- Frontotemporal Dementia
All trials (2)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT05744401 | Phase 2 | Discontinued | — | Alector Inc. |
| NCT04374136 | Phase 3 | Discontinued | Latozinemab | Alector Inc. |
Compounds studied
Trial sites (40)
- Alexandroupoli, Evros, Greece
- Athens, Attica, Greece
- Philadelphia, Pennsylvania, United States
- Lille, France
- Munich, Bavaria, Germany
- Brescia, Lombardy, Italy
- Baggiovara, Italy
- Ulm, Baden-Wurttemberg, Germany
- Getxo, Vizcaya, Spain
- London, Canada
- Rome, Lazio, Italy
- Coimbra, Portugal
- Cologne, Germany
- Porto, Portugal
- Milan, Lombardy, Italy
- New York, New York, United States
- Wroclaw, Lower Silesian Voivodeship, Poland
- Paris, France
- Barcelona, Spain
- Pisa, Italy
- Valencia, Valencia, Spain
- Washington D.C., District of Columbia, United States
- Nashville, Tennessee, United States
- Aurora, Colorado, United States
- Winter Park, Florida, United States
- Bordeaux, France
- Rochester, Minnesota, United States
- Melbourne, Victoria, Australia
- Bristol, Bristol, United Kingdom
- Brescia, Italy
- Port Orange, Florida, United States
- Lisbon, Portugal
- Motherwell, United Kingdom
- Houston, Texas, United States
- Baltimore, Maryland, United States
- Mendoza, Mendoza Province, Argentina
- Basel, Switzerland
- Cincinnati, Ohio, United States
- Córdoba, Córdoba Province, Argentina
- Guildford, Surrey, United Kingdom
Investigator and site data mirrored fromClinicalTrials.gov (public domain).